Status:
COMPLETED
Safety, Blood Levels and Effects of GW642444
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
GW642444 (the study medicine) is a new experimental medicine for treating asthma and chronic obstructive pulmonary disease (COPD). People with asthma and COPD suffer from breathlessness because the sm...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- healthy males and females (of non-childbearing potential) aged 18-55
- body weight \>50kg with BMI 19-29.9 kg/m2
- normal ECG recording
- non-smoker
- Exclusion criteria:
- high blood pressure (above 140/90 mmHg)
- pulse outside range 45 - 90 bpm
- history of breathing problems e.g. asthma
- low haemoglobin (\<11 g/dL)
- blood donation within 56 days of study start
- taking regular medication
- participation in another trial within 4 months of study start
- history of drug or alcohol abuse
- abnormal clinical laboratory tests
- known allergies
Exclusion
Key Trial Info
Start Date :
February 28 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 16 2007
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00469040
Start Date
February 28 2007
End Date
April 16 2007
Last Update
August 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
London, United Kingdom, NW10 7NS